Vericel

Vericel

Biotechnology
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

$2.1B

Market Cap • 9/22/2026

1989

(37 years)

Founded

1997

(29 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

5,6

P/S

6,7

P/EBITDA

66,1

P/OCF

29,6

P/FCF

33,4

P/E

85,6

BVPS

7,1

EPS

0,5

Market Cap

Market Cap

2,1B

EV

2B

EV/Revenue

6,5

EV/EBITDA

63,9

EV/EBIT

109,1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,3%

Total Yield

-0,3%

Payout

0%

Retained Earnings

-380,4M

Profitability

Gross Margin

74,6%

EBITDA Margin

10,2%

EBIT Margin

6%

Net Margin

7,9%

D&A/EBITDA

0%

R&D/Revenue

9,5%

Capex/Revenue

2,6%

Capex/D&A

62%

Capex/OCF

11,5%

SBC/OCF

53,8%

% PPE

33,3%

% Goodwill

0%

ROE

7,2%

ROIC

6,1%

Growth

CAGR Revenue 5Y

15,1%

CAGR Op. Income 5Y

15,8%

CAGR Net Income 5Y

22,5%

CAGR EPS 5Y

21,2%

CAGR OCF 5Y

17,8%

Leverage

N.D./EBITDA

Debt/Equity

0%

Current Ratio

5

Quick Ratio

4,5

Interest Coverage

2849,2%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium